Combination Therapy of Sophoraflavanone B against MRSA: In Vitro Synergy TestingReport as inadecuate




Combination Therapy of Sophoraflavanone B against MRSA: In Vitro Synergy Testing - Download this document for free, or read online. Document in PDF available to download.

Evidence-Based Complementary and Alternative MedicineVolume 2013 2013, Article ID 823794, 7 pages

Research Article

BK21 Plus Team, Professional Graduate School of Oriental Medicine, Wonkwang University, 344-2 Sinyong-dong, Iksan, Chonbuk 570-749, Republic of Korea

Department of Oriental Pharmacy, College of Pharmacy and Wonkwang-Oriental Medicines Research Institute, Wonkang University, 344-2 Sinyong-dong, Iksan, Chonbuk 570-749, Republic of Korea

Department of Herbal Crop Research, National Institute of Horticultural and Herbal Science, RDA, Eumsung, Chungbuk 369-873, Republic of Korea

Received 28 June 2013; Revised 24 September 2013; Accepted 25 September 2013

Academic Editor: Tzeng-Ji Chen

Copyright © 2013 Su-Hyun Mun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Sophoraflavanone B SPF-B, a known prenylated flavonoid, was isolated from the roots of Desmodium caudatum. The aim of this study was to determine the antimicrobial synergism of SPF-B combined with antibiotics against methicillin-resistant Staphylococcus aureus MRSA. MRSA, a multidrug-resistant pathogen, causes both hospital- and community-acquired infections worldwide. The antimicrobial activity of SPF-B was assessed by the broth microdilution method, checkerboard dilution test, and time-kill curve assay. The MIC of SPF-B for 7 strains of S. aureus ranges from 15.6 to 31.25 μg-mL determined. In the checkerboard method, the combinations of SPF-B with antibiotics had a synergistic effect; SPF-B markedly reduced the MICs of the β-lactam antibiotics: ampicillin AMP and oxacillin OXI; aminoglycosides gentamicin GET; quinolones ciprofloxacin CIP and norfloxacin NOR against MRSA. The time-kill curves assay showed that a combined SPF-B and selected antibiotics treatment reduced the bacterial counts below the lowest detectable limit after 24 h. These data suggest that the antibacterial activity of SPF-B against MRSA can be effectively increased through its combination with three groups of antibiotics β-lactams, aminoglycosides, and quinolones. Our research can be a valuable and significant source for the development of a new antibacterial drug with low MRSA resistance.





Author: Su-Hyun Mun, Ok-Hwa Kang, Dae-Ki Joung, Sung-Bae Kim, Yun-Soo Seo, Jang-Gi Choi, Young-Seob Lee, Seon-Woo Cha, Young-Sup A

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents